多发性骨髓瘤对双特异性T细胞衔接器耐药机制及其临床意义
双特异性T细胞衔接器(TCE)正在改变多发性骨髓瘤(MM)的治疗格局,已获批用于三药暴露的复发/难治性MM(RRMM),并正在前线治疗中开展试验。约三分之一的RRMM患者出现原发耐药,多数缓解者最终获得性耐药。本文综述近期研究,从肿瘤内在与外在机制两方面梳理TCE耐药的决定因素,并讨论其临床意义。
要点
- 约三分之一的RRMM患者对双特异性TCE原发耐药,多数缓解者最终出现获得性耐药。
- 肿瘤内在耐药涉及染色体缺失、点突变或表观遗传沉默导致靶抗原丢失,以及MHC I类分子丢失。
- 肿瘤外在耐药涉及耗竭T细胞克隆增多及多种免疫抑制微环境因素,部分机制仅影响一种TCE而不影响其他TCE。
核心结论
- 耐药可由肿瘤内在或肿瘤外在机制引起,部分耐药机制仅损害对一种TCE的应答而保留其他TCE的疗效。
- 监测肿瘤细胞靶抗原状态及免疫环境,对为每位患者选择最合适的TCE及设计MM免疫治疗的联合与序贯策略至关重要。
研究设计与样本
- 综述,汇总近期研究双特异性TCE耐药临床与分子决定因素的研究。
主要发现
- 约三分之一的RRMM患者出现原发耐药,多数缓解者最终发生获得性耐药。
- 肿瘤内在耐药涉及染色体缺失、点突变或表观遗传沉默等导致靶抗原丢失的多种改变。
- 肿瘤内在耐药还包括MHC I类分子丢失,从而阻止MHC I类分子与T细胞受体(TCR)的共刺激信号传导。
- 肿瘤外在耐药涉及大量耗竭T细胞克隆及多种产生免疫抑制微环境的因素。
- 部分耐药机制损害对一种TCE的应答,同时保留其他TCE的疗效。
临床怎么用
- 监测肿瘤细胞靶抗原状态及其免疫环境,是选择最合适TCE及设计MM免疫治疗联合与序贯策略的关键。
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bispecific T-cell engagers (TCEs) are revolutionizing patient care in multiple myeloma (MM). These monoclonal antibodies, that redirect T cells against cancer cells, are now approved for the treatment of triple-class exposed relapsed/refractory MM (RRMM). They are currently tested in earlier lines of the disease, including in first line. Yet, primary resistance occurs in about one-third of patients with RRMM, and most responders eventually develop acquired resistance. Understanding the mechanisms of resistance to bispecific TCE is thus essential to improve immunotherapies in MM. Here, we review recent studies investigating the clinical and molecular determinants of resistance to bispecific TCE. Resistance can arise from tumor-intrinsic or tumor-extrinsic mechanisms. Tumor-intrinsic resistance involves various alterations leading to the loss of the target antigen, such as chromosome deletions, point mutations, or epigenetic silencing. Loss of major histocompatibility complex (MHC) class I, preventing MHC class I: T-cell receptor (TCR) costimulatory signaling, was also reported. Tumor-extrinsic resistance involves abundant exhausted T-cell clones and several factors generating an immunosuppressive microenvironment. Importantly, some resistance mechanisms impair response to 1 TCE while preserving the efficacy of others. We next discuss the clinical implications of these findings. Monitoring the status of target antigens in tumor cells and their immune environment will be key to select the most appropriate TCE for each patient and to design combination and sequencing strategies for immunotherapy in MM.
引用
- Letouzé E, Moreau P, Munshi N, et al. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. Blood Adv. 2024. PMID: 38513088. doi:10.1182/bloodadvances.2023012354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。